Japan Approves the World’s First Treatment Made With Reprogrammed Human Cells
By Ritsuko Kawai,
Wired
| 03. 14. 2026
Researchers in Japan pioneered reprogrammed cells 20 years ago. Now the country has given the first-ever authorizations to manufacture and sell medical products based on the technology.
On March 6, Japan’s Ministry of Health, Labor and Welfare officially granted conditional and time-limited marketing authorization to two regenerative medical products derived from reprogrammed iPS cells, marking exactly 20 years since the creation of mouse iPS cells.These will be the world's first practical application of iPS cell-derived products.
“We are very pleased to have taken a major step toward social application on the 20th anniversary of the announcement of mouse iPS cells,” said Shinya Yamanaka, director emeritus of the iPS Cell Research Institute at Kyoto University. “To establish it as a medical treatment, it is essential to go through the process of confirming its safety and efficacy in many more cases. I believe it is important that we continue to move forward steadily, step by step, with scientific caution and without getting carried away.”
What Are iPS cells?
The initialism stands for induced pluripotent stem cells. These are adult cells, such as skin or blood cells, that have been reprogrammed to function like embryonic stem cells. They can divide indefinitely and can take the form of any cell...
Related Articles
By David Jensen, The California Stem Cell Report | 03.26.2026
SACRAMENTO, Ca. -- California’s $12 billion stem cell and gene therapy program scored a historic first today, announcing that it had for the first time helped to finance a revolutionary treatment that will now be available to the general public...
Cathy Tie seems to be good at starting businesses but not so dedicated to maintaining them. CGS, like many others, first heard of her thanks to Caiwei Chen and Antonio Regalado in MIT Technology Review, May 2025, as the partner (perhaps bride) of the notorious Chinese scientist He Jiankui, described in the headline as “China’s Frankenstein.” He prefers “Chinese Darwin.” She ran his Twitter account for a while, contributing such gems as:
Get in luddite, we’re going gene editing...
By Laura DeFrancesco, Nature Biotechnology | 03.17.2026
The first gene editors designed to fix genetic lesions in mutation-agnostic ways are poised to enter the clinic. Tessera Therapeutics and Alltrna, two Flagship Pioneering-funded companies, are gearing up to test novel genetic medicines in humans. Tessera received regulatory clearance...
By Darren Incorvaia, Fierce Biotech | 03.11.2026
A new method for safely inserting large chunks of DNA into genomes has now measured up in mice, potentially paving the way for the next generation of gene editing medicines.
The approach, which is described in a Nature paper...